^
Association details:
| Biomarker: | High HDAC6 score + HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | rocilinostat (ACY-1215) (HDAC6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
645 - Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat
Published date:
03/10/2021
Excerpt:
...high HDAC6 scores. Based on these results, we designed a phase Ib clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients...Study results showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2- disease, and that the HDAC6 score was predictive of response.
Secondary therapy:
albumin-bound paclitaxel
